MDN1 and breast cancer: As immunohistochemistry results demonstrated that some breast cancer tissue expressed higher levels of midasin compared to normal breast tissue samples, it was important to examine the clinical relevance of midasin levels on patient survival and determine within this context whether hormone receptor status was relevant to patient outcomes.